Organization (Other)
Hospital Authority, Hong Kong
ClinicalTrials.gov lists Hospital Authority, Hong Kong as lead sponsor of 79 trials. It has 6 active development programs and 23 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Hospital Authority, Hong Kong: 79 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (110)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 8 |
| Constipation | 5 |
| Hypertension | 5 |
| Renal Insufficiency, Chronic | 5 |
| Schizophrenia | 5 |
Showing 5 of 110 disease areas.
Trials by start year as sponsor or collaborator (24)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 9 |
| 2024 | 5 |
| 2023 | 6 |
| 2022 | 2 |
| 2021 | 6 |
| 2020 | 10 |
| 2019 | 4 |
| 2018 | 4 |
| 2017 | 1 |
Showing 10 of 24 years.
Prediction, not a registry value: median of 25 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; registered median of 13 months across 10 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (6)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Aqueous Cream | Vitiligo | Phase 2/3 | 1 |
| Ruxolitinib Cream 1.5% | Vitiligo | Phase 2/3 | 1 |
| Empagliflozin 10 MG | Inflammation | Not reported | 1 |
| Empagliflozin 10 MG | Critical Illness | Not reported | 1 |
| Empagliflozin 10 MG | Sepsis | Not reported | 1 |
Showing 5 of 6 active programs.
Approved assets (23)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| non-renin angiotensin system blockers | 1 |
| Renin angiotensin system blockers | 1 |
| Faricimab Injection [Vabysmo] | 1 |
| Ketorolac | 1 |
| Methoxyflurane | 1 |
Showing 5 of 23 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 86% hit target (n=7) | 33% on time (n=6) |
Journals published in (208)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 9 |
| The Cochrane database of systematic reviews | 7 |
| Surgical endoscopy | 6 |
| International journal of nursing studies | 5 |
| Journal of advanced nursing | 5 |
Showing 5 of 208 journals.
Organization relationships (6)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| The Hong Kong Polytechnic University | Co sponsors trial with | 3 |
| Hong Kong Nasopharyngeal Cancer Study Group Limited | Co sponsors trial with | 2 |
| The Hong Kong Blood Cancer Foundation | Co sponsors trial with | 1 |
| Fresienius Kabi HK Ltd | Co sponsors trial with | 1 |
| Vigconic (International) Ltd. | Co sponsors trial with | 1 |
Showing 5 of 6 relationships.
Latest dated events (127)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07-16 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-08-21 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 127 events.
Biomarker capability evidence (54)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| AMT | Trial collaborator | Named in trial inclusion criteria |
| CHP1 | Trial collaborator | Named in trial inclusion criteria |
| CHP1 | Trial collaborator | Named in trial inclusion criteria |
| CLN3 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 54 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.